NCT04352907

Brief Summary

To determine the performance of the Dexcom CGM device in comparison to arterial glucose samples.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 15, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 20, 2020

Completed
7 months until next milestone

Study Start

First participant enrolled

November 6, 2020

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2022

Completed
Last Updated

June 2, 2022

Status Verified

May 1, 2022

Enrollment Period

1.8 years

First QC Date

April 15, 2020

Last Update Submit

May 31, 2022

Conditions

Keywords

insulin infusioncontinuous glucose sensor

Outcome Measures

Primary Outcomes (1)

  • Continous Glucose Sensor values (CGM)

    CGM will be compared with arterial glucose values

    3 to 7 consecutive days

Secondary Outcomes (1)

  • Vasopressor Use

    3 to 7 consecutive days

Interventions

Continuous glucose sensor results will be compared with arterial glucose samples

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects in the Intensive Care Unit

You may qualify if:

  • minimum age 18 years
  • anticipated to be on an insulin infusion for 3-7 consecutive days
  • of these subjects will be on vasopressors who will be receiving large volume fluid resuscitation

You may not qualify if:

  • subjects not on insulin infusion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vancouver General Hospital

Vancouver, British Columbia, V5Z 1M9, Canada

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Central Study Contacts

David M Thompson, MD

CONTACT

Barbara J Allan, MHA

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Assistant Professor

Study Record Dates

First Submitted

April 15, 2020

First Posted

April 20, 2020

Study Start

November 6, 2020

Primary Completion

September 1, 2022

Study Completion

September 1, 2022

Last Updated

June 2, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations